|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL43 |
Gene summary for MRPL43 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL43 | Gene ID | 84545 |
| Gene name | mitochondrial ribosomal protein L43 | |
| Gene Alias | L43mt | |
| Cytomap | 10q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | Q8N983 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84545 | MRPL43 | LZE4T | Human | Esophagus | ESCC | 4.81e-15 | 5.28e-01 | 0.0811 |
| 84545 | MRPL43 | LZE5T | Human | Esophagus | ESCC | 3.13e-05 | 6.91e-01 | 0.0514 |
| 84545 | MRPL43 | LZE7T | Human | Esophagus | ESCC | 3.56e-10 | 4.56e-01 | 0.0667 |
| 84545 | MRPL43 | LZE8T | Human | Esophagus | ESCC | 2.57e-15 | 7.31e-01 | 0.067 |
| 84545 | MRPL43 | LZE20T | Human | Esophagus | ESCC | 8.00e-07 | 5.15e-01 | 0.0662 |
| 84545 | MRPL43 | LZE22T | Human | Esophagus | ESCC | 8.77e-11 | 5.61e-01 | 0.068 |
| 84545 | MRPL43 | LZE24T | Human | Esophagus | ESCC | 1.17e-36 | 1.46e+00 | 0.0596 |
| 84545 | MRPL43 | LZE6T | Human | Esophagus | ESCC | 8.64e-12 | 9.24e-01 | 0.0845 |
| 84545 | MRPL43 | P1T-E | Human | Esophagus | ESCC | 9.94e-15 | 9.19e-01 | 0.0875 |
| 84545 | MRPL43 | P2T-E | Human | Esophagus | ESCC | 6.11e-77 | 1.45e+00 | 0.1177 |
| 84545 | MRPL43 | P4T-E | Human | Esophagus | ESCC | 9.56e-61 | 1.70e+00 | 0.1323 |
| 84545 | MRPL43 | P5T-E | Human | Esophagus | ESCC | 2.93e-70 | 1.47e+00 | 0.1327 |
| 84545 | MRPL43 | P8T-E | Human | Esophagus | ESCC | 1.53e-41 | 8.85e-01 | 0.0889 |
| 84545 | MRPL43 | P9T-E | Human | Esophagus | ESCC | 4.16e-24 | 7.44e-01 | 0.1131 |
| 84545 | MRPL43 | P10T-E | Human | Esophagus | ESCC | 1.11e-34 | 5.82e-01 | 0.116 |
| 84545 | MRPL43 | P11T-E | Human | Esophagus | ESCC | 1.60e-33 | 1.42e+00 | 0.1426 |
| 84545 | MRPL43 | P12T-E | Human | Esophagus | ESCC | 7.46e-75 | 1.32e+00 | 0.1122 |
| 84545 | MRPL43 | P15T-E | Human | Esophagus | ESCC | 7.40e-56 | 1.26e+00 | 0.1149 |
| 84545 | MRPL43 | P16T-E | Human | Esophagus | ESCC | 1.99e-67 | 1.22e+00 | 0.1153 |
| 84545 | MRPL43 | P17T-E | Human | Esophagus | ESCC | 1.66e-17 | 9.42e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:0032543 | Liver | Cirrhotic | mitochondrial translation | 40/4634 | 76/18723 | 1.61e-07 | 4.29e-06 | 40 |
| GO:0140053 | Liver | Cirrhotic | mitochondrial gene expression | 49/4634 | 108/18723 | 2.35e-06 | 4.31e-05 | 49 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:01400533 | Oral cavity | OSCC | mitochondrial gene expression | 78/7305 | 108/18723 | 2.37e-12 | 9.86e-11 | 78 |
| GO:00325434 | Oral cavity | OSCC | mitochondrial translation | 59/7305 | 76/18723 | 7.21e-12 | 2.70e-10 | 59 |
| GO:003254313 | Oral cavity | LP | mitochondrial translation | 43/4623 | 76/18723 | 2.85e-09 | 1.26e-07 | 43 |
| GO:014005312 | Oral cavity | LP | mitochondrial gene expression | 53/4623 | 108/18723 | 3.54e-08 | 1.27e-06 | 53 |
| GO:00325433 | Prostate | BPH | mitochondrial translation | 23/3107 | 76/18723 | 2.21e-03 | 1.22e-02 | 23 |
| GO:01400532 | Prostate | BPH | mitochondrial gene expression | 29/3107 | 108/18723 | 4.68e-03 | 2.25e-02 | 29 |
| GO:003254312 | Prostate | Tumor | mitochondrial translation | 24/3246 | 76/18723 | 1.73e-03 | 1.03e-02 | 24 |
| GO:014005311 | Prostate | Tumor | mitochondrial gene expression | 31/3246 | 108/18723 | 2.31e-03 | 1.30e-02 | 31 |
| GO:00325436 | Skin | cSCC | mitochondrial translation | 47/4864 | 76/18723 | 4.70e-11 | 2.22e-09 | 47 |
| GO:01400535 | Skin | cSCC | mitochondrial gene expression | 56/4864 | 108/18723 | 8.06e-09 | 2.56e-07 | 56 |
| GO:01400536 | Thyroid | PTC | mitochondrial gene expression | 51/5968 | 108/18723 | 6.04e-04 | 3.83e-03 | 51 |
| GO:00325437 | Thyroid | PTC | mitochondrial translation | 38/5968 | 76/18723 | 7.52e-04 | 4.67e-03 | 38 |
| GO:014005314 | Thyroid | ATC | mitochondrial gene expression | 51/6293 | 108/18723 | 2.26e-03 | 1.06e-02 | 51 |
| GO:003254315 | Thyroid | ATC | mitochondrial translation | 38/6293 | 76/18723 | 2.26e-03 | 1.06e-02 | 38 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL43 | insertion | Frame_Shift_Ins | novel | c.22_23insCA | p.Ser8ThrfsTer23 | p.S8Tfs*23 | Q8N983 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| MRPL43 | SNV | Missense_Mutation | c.418N>C | p.Phe140Leu | p.F140L | Q8N983 | protein_coding | tolerated(1) | benign(0) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPL43 | SNV | Missense_Mutation | novel | c.140N>C | p.Val47Ala | p.V47A | Q8N983 | protein_coding | deleterious(0.01) | benign(0.348) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| MRPL43 | SNV | Missense_Mutation | rs141726768 | c.484N>A | p.Gly162Ser | p.G162S | Q8N983 | protein_coding | tolerated_low_confidence(0.62) | benign(0.001) | TCGA-53-A4EZ-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
| MRPL43 | SNV | Missense_Mutation | novel | c.125G>A | p.Gly42Asp | p.G42D | Q8N983 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-55-6969-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MRPL43 | SNV | Missense_Mutation | novel | c.676N>C | p.Ser226Pro | p.S226P | Q8N983 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-56-7731-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL43 | SNV | Missense_Mutation | novel | c.247N>A | p.Ala83Thr | p.A83T | Q8N983 | protein_coding | tolerated(0.29) | benign(0.017) | TCGA-UF-A7JT-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| MRPL43 | SNV | Missense_Mutation | c.122N>A | p.Arg41His | p.R41H | Q8N983 | protein_coding | deleterious(0.02) | possibly_damaging(0.899) | TCGA-BR-A4QI-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |